Previous research on non-diabetic mice with experimentally induced preeclampsia involved administering angiotensin II type 1 receptor autoantibodies on gestation day 13, followed by daily oral treatment with empagliflozin until gestational day 19. This evidence concerns the gene AGTR1 and preeclampsia.